Editorial Board Members’ Collection Series: Hepatitis Viruses: Who They Are and Consequences
A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Virology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 1772
Special Issue Editors
Interests: HBV variants; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals
Interests: hepatitis viruses; HIV; SARS-CoV-2; influenza; emerging viruses; viral genomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Viral hepatitis includes several universal infectious diseases (HV) which have in common an inflammation of liver cells linked to viruses: the enteric HAV, and HEV, and the parenterally-transmitted viruses, HBV, HCV, and HDV, this last requiring HBV co-infection. Chronic viral hepatitis C, B and Delta are diseases that are most often silent, asymptomatic, responsible for significant morbidity and mortality worldwide, for which the World Health Organization (WHO) has set the elimination objective by 2030 (90% of patients diagnosed and 80% of patients treated). More than 290 million people worldwide live with HBV and around 58 million with HCV. An estimated 1.3 million people died from chronic viral hepatitis B and C in 2022. Around 90% of HBV or HCV infected patients are unaware of their status, making difficult to accomplish the 2030 objective. Although there is a highly effective vaccine against HAV, HBV (also preventing HDV infection) and HEV, and a highly effective treatment against HCV, to control the burden of these diseases, a combination of vaccination and availability of effective treatment is then needed. The aim of this special issue is to point the essential issues for each of those viral infection, to achieve the elimination objective by 2030.
Special topics:
- Hepatitis A vaccine: who and where?
- Zoonotic hepatitis E genotypes and persistence.
- HBV emerging therapies.
- Programs of HBV universal vaccination
- Removing barriers to HBV and HCV care cascades.
- Managing HBV chronic carriers and sequelae.
- HCV redoubts limiting elimination.
- HCV vaccine.
- Clarifying the enigma around HDV.
Expected papers:
- Update on the use of the hepatitis A vaccine?
- What are the new data regarding hepatitis E?
- Where is the epidemiology of hepatitis C that can be cured?
- HCV infection and PWID
- Hemodialysis: an HCV redoubt.
- Illustration of the substantial disparities in HBV burden between countries and regions but also within a country or region, income, race or ethnicity, and other social and cultural factors.
- How to improve the management of cirrhosis and liver cancer HBV-related deaths, (acute flares and reactivation, extrahepatic complications, and social stigma)?
- Current programs regarding Universal infant vaccination with timely birth dose and peripartum antiviral prophylaxis in mothers with a high level of HBV DNA?
- How to improve Underdiagnosis and low treatment rates of chronic HBV infection are serious even in high-income countries and exacerbated in low-income countries?
- What actions to remove the barriers that disrupt the current HBV care cascade and to close the gaps in HBV prevention, screening, diagnosis, linkage to care, antiviral treatment and liver cancer surveillance? Towards the integration of quality of life measurement and cost-effectiveness calculations in clinical trials?
Dr. Isabelle Chemin
Prof. Dr. Flor Helene Pujol
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viral hepatitis
- liver
- pathogenesis
- cancer
- fibrosis
- natural history
- treatments
- epidemiology
- vaccine
- genotypes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.